



Harald Stein

Contact

Harald Stein

Publications (16)

Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. *Lancet Haematol* 2021; 8:e398–e409.

Hartmann S, Hansmann M, Engert A, Rosenwald A, Möller P, Klapper W, Stein H, Quintanilla-Martinez L, Fend F, Cogliatti S, Ott G, Feller A, Bernd H, Mottok A, Plütschow A, Eichenauer D. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. *Am J Hematol* 2019; 94:1208–1213.

Loeffler-Wirth H, Pott C, Schwaenen C, Trautmann H, Wessendorf S, Stein H, Szczepanowski M, Trümper L, Hummel M, Klapper W, Siebert R, Loeffler M, Binder H, Rosenwald A, Ott G, Kreuz M, Hopp L, Arakelyan A, Haake A, Cogliatti S, Feller A, Hansmann M, Lenze D, Möller P, Müller-Hermelink H, Fortenbacher E, Willscher E, German Cancer Aid consortium Molecular Mechanisms for Malignant Lymphoma. A modular transcriptome map of mature B cell lymphomas. *Genome Med* 2019; 11:27.

Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2017; 390:2790–2802.

Paul U, Stein H, Hansmann M, Möller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Trümper L, Siebert R, Cogliatti S, Feller A, Rosenwald A, Richter J, Stuhlmann-Laiasz C, Kreuz M, Nagel I, Horn H, Staiger A, Aukema S, Hummel M, Ott G, Spang R, Klapper W. Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. *Leuk Lymphoma* 2017;1–9.

Staiger A, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, Hansmann M, Lenze D, Ziepert M, Horn H, Scott D, Barth T, Bernd H, Feller A, Klapper W, Szczepanowski M, Hummel M, Stein H, German High-Grade Lymphoma Study Group. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2017; 35:2515–2526.

Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet* 2014; 385:1418–27.

Hartmann S, Engert A, Hansmann M, Stein H, Rosenwald A, Möller P, Ott G, Feller A, Hummel M, Cogliatti S, Bernd H, Koch K, Bob R, Mottok A, Plütschow A, Eichenauer D, Klapper W. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma—a matched pair analysis from the German Hodgkin Study Group (GHSG). *Br J Haematol* 2014; 167:238–42.

Aukema S, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin P, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project, Schwaenen C, Szczepanowski M, Rosenwald A, Kreuz M, Kohler C, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Cogliatti S. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. *Haematologica* 2013; 99:726-35.

Hartmann S, Engert A, Hansmann M, Stein H, Rosenwald A, Möller P, Ott G, Feller A, Hummel M, Cogliatti S, Bernd H, Koch K, Bob R, Mottok A, Plütschow A, Eichenauer D, Klapper W. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). *Blood* 2013; 122:4246-52; quiz 4292.

Horn H, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, Möller P, Schmelter C, Hansmann M, Ziepert M, Becher C, Barth T, Bernd H, Feller A, Klapper W, Hummel M, Stein H, German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. *Blood* 2013; 121:2253-63.

Ott G, Frank M, Hansmann M, Barth T, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Müller-Hermelink H, Stein H, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H, Thorns C, Feller A, Lenze D, Hummel M, Rosenwald A. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. *Blood* 2010; 116:4916-25.

Bernd H, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller A, Barth T, Müller-Hermelink H, Rosenwald A, Ziepert M, Thorns C, Klapper W, Wacker H, Hummel M, Stein H, Hansmann M, Ott G, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. *Haematologica* 2009; 94:1569-80.

Klapper W, Möller P, Barth T, Müller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken J, Wacker H, Unterhalt M, Hiddemann W, Dreyling M, Stein H, Loddenkemper C, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd H, Cabeçadas J, Campo E, Cogliatti S, Hansmann M, Kluin P, Kodet R, Krivolapov Y, for the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. *Journal of hematopathology* 2009

Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, Seifert M, Schübeler D, Schwaenen C, Rosenwald A, Prosper F, Pott C, Ott G, Möller P, Macleod R, Stürzenhofecker B, Weber M, Siebert R, Hasenclever D, Barker D, Esteller M, Spang R, Stein H, Trümper L, Loeffler M, Wessendorf S, Küppers R, Korn B, Ballestar E, Lopez-Serra L, Richter J, Rosolowski M, Wickham-Garcia E, Ammerpohl O, Bentink S, Bibikova M, Kreuz M, Berger H, Agirre X, Klapper W, Hummel M, Hansmann M, Fraga M, Fan J, Drexler H, Cogliatti S, Calvanese V, Bernd H, Martín-Subero J. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. *Blood* 2009; 113:2488-97.

Dierlamm J, Cogliatti S, Möller P, Schwaenen C, Stein H, Löffler M, Spang R, Trümper L, Siebert R, Ott G, Haralambieva E, Murga Penas E, Bentink S, Wessendorf S, Berger H, Hummel M, Klapper W, Lenze D, Rosenwald A, Deutsche Krebshilfe Network Project "Molecular Mechanisms in Malignant Lymphomas". Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. *Haematologica* 2008; 93:688-96.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch